Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data BioNTech SE files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
61.6
128
109
482
18,977
17,311
3,819
2,751
2,870
Cost of revenue
9.32
13.7
17.4
59.3
2,912
2,995
600
541
642
Gross profit
52.3
114
91.2
423
16,065
14,316
3,219
2,210
2,228
Research and development
85.5
143
227
645
949
1,537
1,783
2,254
2,105
Operating income
-61.3
-53.9
-182
-82.4
15,284
12,643
690
-1,314
-1,405
Interest expense
26
0.05
2
65
305
18.9
23.9
27.4
69.8
Interest income
2.13
8.05
4.1
1.6
67.7
330
520
664
424
Pre-tax income
-85.9
-47.7
-179
-146
15,046
12,954
1,186
-678
-1,051
Income tax
0.05
0.6
-0.2
-161
4,754
3,520
256
-12.4
85.3
Net income to minority interests
-0.3
-0.24
-0.1
0
0
Net income
-85.7
-48
-179
15.2
10,293
9,434
930
-665
-1,136
EPS, basic
-0.51
-0.25
-0.85
0.06
42.18
38.78
3.87
-2.77
-4.70
EPS, diluted
-0.51
-0.25
-0.85
0.06
39.63
37.77
3.83
-2.77
-4.70
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
172
412
519
1,210
1,693
13,875
11,664
9,762
7,675
Receivables
166
12,382
7,146
2,156
1,464
924
Inventory
5.79
11.7
64.1
503
440
358
283
111
Total current assets
449
560
1,667
15,072
21,922
19,527
18,804
16,147
Property, plant and equipment
49.6
66.2
93
227
323
609
757
935
1,081
Lease right-of-use assets
49.8
55
99
198
212
214
248
210
Goodwill
2.98
53.7
57.8
61.2
363
381
368
Total assets
653
798
2,319
15,831
23,279
23,006
22,530
21,989
Accounts payable
102
160
204
354
427
535
Short-term debt
5.31
9.1
130
Total current liabilities
126
138
606
3,482
2,951
2,071
2,523
2,142
Lease liabilities
48.6
54.1
78.1
154
174
189
215
185
Total liabilities
386
304
947
3,937
3,224
2,760
3,119
2,764
Retained earnings
410
9,883
18,833
19,763
19,098
17,962
Shareholders' equity
266
493
Minority interests
0.85
Total equity
-48.2
267
494
1,372
11,894
20,056
20,246
19,411
19,224
Total liabilities and equity
653
798
2,319
15,831
23,279
23,006
22,530
21,989
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-86
-48.3
-179
15.2
10,293
9,434
930
-665
-1,136
Cash from operations
-52.6
-58.9
-199
-13.5
890
13,577
5,371
208
456
Capital expenditures
-24.3
-29.9
-38.6
-66
-128
-329
-249
-287
-175
Cash from investing
-52.5
-66.5
-77.2
-145
-566
-35.3
-6,955
-2,081
-2,469
Debt issued
5.6
11
156
0
0.8
0.3
0
6.7
Debt repaid
0
-1.6
-52.6
-18.8
-0.1
-2.3
-18
Stock issued
362
375
753
161
111
0
0
Dividends paid
0
0
-484
0
0
Cash from financing
-1.64
365
383
895
94.2
-1,419
-779
-45.9
-52.9
Exchange rate effect
-24.8
-0.46
0
-45.3
64.7
60.1
-14.5
14.8
-27
Free cash flow
-76.9
-88.8
-237
-79.5
762
13,248
5,122
-78.8
281
Interest paid
0.73
1.77
2
3.6
12.2
21.5
5.4
13.5
11
Income taxes paid
0.05
0.3
-0.2
-0.5
3,458
4,222
483
389
-3.8
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
77.6%
Gross profit / revenue.
Operating margin
-49.0%
Operating income / revenue.
Pre-tax margin
-36.6%
Pre-tax income / revenue.
Net margin
-39.6%
Net income / revenue.
FCF margin
9.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
15.9%
Cash from operations / revenue.
Return on assets (ROA)
-5.1%
Net income / average total assets.
R&D / revenue
73.3%
Research and development expense / revenue.
Capex / revenue
6.1%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
4.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-45.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
42.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
0.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-46.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
39.4%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
119.5%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y
-67.7%
Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 3y
-72.3%
Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-2.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-1.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
56.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.54x
Current assets / current liabilities.
Quick ratio
4.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.58x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
12.6%
Total liabilities / total assets.
Interest coverage
-20.1x
Operating income / interest expense.
Working capital
€14.00B
Current assets - current liabilities.
Goodwill and intangibles / assets
1.7%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.13x
Revenue / average total assets.
Fixed asset turnover
2.85x
Revenue / average property, plant and equipment.
Inventory turnover
3.26x
Cost of revenue / average inventory.
Days inventory
112 days
365 x average inventory / cost of revenue.
Receivables turnover
2.40x
Revenue / average receivables.
Days sales outstanding
152 days
365 x average receivables / revenue.
Days payables
273 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-10 days
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
38.4%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€4.70
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€4.70
Net income per basic share, as reported (split-adjusted).
What was BioNTech SE's revenue in fiscal 2025?
BioNTech SE reported revenue of €2.87B for fiscal 2025, 4.3% higher than the year before.
Was BioNTech SE profitable in fiscal 2025?
No. It reported a net loss of €1.14B.
How much free cash flow did BioNTech SE generate in fiscal 2025?
Cash from operations of €456.0M minus capital expenditures of €175.1M left free cash flow of €280.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.